<DOC>
	<DOCNO>NCT00024167</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radioactive substance strontium-89 may relieve bone pain associated prostate cancer . It yet know whether chemotherapy effective without strontium-89 treat bone metastasis . PURPOSE : This randomized phase III trial study give chemotherapy together strontium-89 see well work compare chemotherapy alone treat patient prostate cancer spread bone .</brief_summary>
	<brief_title>Chemotherapy With Without Strontium-89 Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effectiveness , term overall survival , consolidation therapy without strontium chloride Sr 89 induction chemotherapy patient androgen-independent prostate cancer . OUTLINE : This randomize study . Patients stratify accord type induction chemotherapy ( KAVE v prednisone docetaxel ) , number bony metastasis ( 20 vs 20 ) , Eastern Cooperative Oncology ( ECOG ) performance status ( 0-1 v 2-3 ) , use zoledronate ( yes v ) . - Induction therapy : Patients receive 1 2 induction therapy regimen . - Regimen A ( KAVE ) : Patients receive doxorubicin IV 24 hour day 1 oral ketoconazole three time daily day 1-7 week 1 , 3 , 5 . Patients receive vinblastine IV 30 minute day 1 oral estramustine three time daily day 1-7 week 2 , 4 , 6 . Patients receive treatment week 7 8 . Treatment repeat every 8 week least 2 courses* absence disease progression unacceptable toxicity . NOTE : *Patients continue receive oral ketoconazole three time daily disease progression . - Regimen B ( prednisone docetaxel ) : Patients receive oral prednisone twice daily day 1-21 ( day 1-14 course 5 ) docetaxel IV 1 hour day 1 . Treatment repeat every 21 day least 5 course absence disease progression unacceptable toxicity . - Consolidation therapy : Patients prostate-specific antigen ( PSA ) response ( least 50 % decline PSA level baseline week 16 OR least 2 PSA level decrease least 50 % baseline ) randomize 1 2 consolidation treatment arm . - Arm I : Patients receive doxorubicin IV 24 hour weekly 6 week plus strontium chloride Sr 89 IV begin chemotherapy . - Arm II : Patients receive doxorubicin arm I . Patients follow every 4 week PSA progression every 3 month thereafter . PROJECTED ACCRUAL : Approximately 480 patient ( 240 randomize ) accrue study within 48 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Rising PSA least 2 occasion &gt; 1 week apart ( minimum value 5 ng/ml ) , accompany either bone pain , patient asymptomatic , worsen bone scan new lesion period &lt; 6 month 2 . Patients antiandrogens discontinue flutamide nilutamide least 4 week bicalutamide 6 week ; If progression document time interval inclusion criterion # 1 , patient eligible 3 . Osteoblastic metastasis bone scan CT scan 4 . Androgenindependent prostate adenocarcinoma 5 . Castrate testosterone level &lt; /= 50 ng/ml ; treatment maintain castrate level testosterone must continue 6 . &gt; /= 18 year age 7 . Life expectancy great equal 12 week 8 . Zubrod performance status &lt; /= 3 9 . Patients must normal organ marrow function define : Leukocytes great 3,000/mcL Absolute neutrophil count great 1,500/mcL Platelets great 100,000/mcL Total bilirubin less equal 2X institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) less equal 2X institutional upper limit normal 10 . The patient must ability understand willingness sign write informed consent document 11 . Participating subject female partner agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation 1 . History allergic reaction attribute compound similar chemical biologic composition agent use trial 2 . Prior doxorubicin , vinblastine KAVE arm prior docetaxel prednisone plus docetaxel arm . However , previous treatment use secondary hormonal agent ( aminoglutethimide , diethylstilbesterol , estramustine ) , steroid ( dexamethasone , prednisone , hydrocortisone ) , angiogenesis inhibitor , gene therapy , immunotherapy allow 3 . More one prior cytotoxic treatment 4 . Prior Sr89 Sm153 treatment 5 . Patients chemotherapy , immunotherapy , radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier 6 . Previous vagotomy condition ( pernicious anemia ) associate achlorhydria . Patients active peptic ulcer disease still require regular use H2 blocker ( cimetidine [ Tagamet ] , ranitidine [ Zantac ] , famotidine [ Pepcid ] , etc ) , proton pump inhibitor ( omeprazole [ Prilosec ] ) , antacid ( Mylanta , Maalox , Tums , etc ) week 16 induction chemotherapy ( option 1 ) might suitable randomization 7 . Predominant visceral metastasis liver , lung , brain 8 . Symptomatic lymphadenopathy ( scrotal pedal edema ) significant local invasive disease ( hematuria ) 9 . Small cell carcinoma 10 . Recent history transient ischemic attack ( TIA ) myocardial infarction ( MI ) within 12 month , active angina claudication sufficient limit activity 11 . Active likely become active second malignancy ( nonmelanoma skin cancer ) 12 . Uncontrolled intercurrent illness : include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>Strontium-89</keyword>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Androgen-Independent Prostate Cancer</keyword>
</DOC>